DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2670
+0.0020 (+0.75%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2650
Open0.2674
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.2636 - 0.2700
52 Week Range0.2300 - 21.5000
Volume89,776
Avg. Volume188,327
Market Cap2.602M
Beta (3Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-2.748
Earnings DateMar 23, 2017 - Mar 24, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire26 days ago

    Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

    Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

  • GlobeNewswirelast month

    Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. In July, the Company announced that it has amended the protocol for the FOCUS trial, which is now enrolling as a single-arm, multi-center open label study. Safety data collected have not been modified as a result of the amendment, and safety data from both the randomized and single-arm protocols will be pooled in any analyses submitted to the Food & Drug Administration as part of a New Drug Application.

  • GlobeNewswire2 months ago

    Delcath Announces Third Quarter Fiscal 2018 Financial Results

    NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces.